Department of Occupational and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, PR China; Key Laboratory of Environment and Health, Ministry of Education & Ministry of Environmental Protection, and State Key Laboratory of Environmental Health (Incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, PR China.
State Key Laboratory of Organic Geochemistry, Guangdong Key Laboratory of Environment and Resources, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, Guangzhou 510640, China.
Sci Total Environ. 2018 Mar;616-617:841-854. doi: 10.1016/j.scitotenv.2017.10.238. Epub 2017 Nov 6.
Exposure to polycyclic aromatic hydrocarbons (PAHs) could cause high blood pressure (BP) and increased risk for atherosclerotic cardiovascular disease (ASCVD). However, the mechanisms underlying the relationship between them were unclear. We investigated potential mediation effect of obesity on the association of exposure to PAHs with high BP and increased risk for ASCVD. In the repeated measures study, 106 community-dwelling residents in Wuhan, China finished the physical examination in the winter and summer seasons, eight urinary PAHs metabolites were measured. Associations of urinary PAHs with high BP and increased risk for ASCVD were assessed using either linear mixed effect models or generalized estimating equations models. Mediation analysis was performed to evaluate the mediating effect of obesity on the association of urinary PAHs metabolites with high BP or increased risk of ASCVD. We observed the positive association between urinary PAHs metabolites and BP or the odds ratios for high BP (all P<0.05). Additionally, each one-unit increase in ln-transformed urinary levels of 4-hydroxyphenanthrene or the total of PAH metabolites was associated with a 12.63% or 11.91% increase in the estimated 10-year ASCVD risk (both P<0.05). The waist-to-height ratio mediated 29.0% of the association of urinary 4-hydroxyphenanthrene with increased risk of ASCVD (P<0.05). The findings suggest that PAHs exposure may be associated with elevated BP and an increased risk of ASCVD. Obesity may partially mediate the association between PAHs exposure and higher BP or increased risk of ASCVD.
多环芳烃（PAHs）暴露可能导致高血压（BP）和动脉粥样硬化性心血管疾病（ASCVD）风险增加。然而，它们之间关系的机制尚不清楚。我们研究了肥胖对多环芳烃暴露与高血压和 ASCVD 风险增加之间关系的潜在中介作用。在重复测量研究中，中国武汉的 106 名社区居民在冬季和夏季完成了体检，测量了 8 种尿多环芳烃代谢物。使用线性混合效应模型或广义估计方程模型评估尿多环芳烃与高血压和 ASCVD 风险增加之间的关联。进行中介分析以评估肥胖对尿多环芳烃代谢物与高血压或 ASCVD 风险增加之间关联的中介作用。我们观察到尿多环芳烃代谢物与 BP 之间存在正相关，或与高血压的比值比（所有 P<0.05）。此外，ln 转换的尿中 4-羟基菲或多环芳烃代谢物总量每增加一个单位，估计的 10 年 ASCVD 风险就会增加 12.63%或 11.91%（均 P<0.05）。腰围身高比介导了尿中 4-羟基菲与 ASCVD 风险增加之间关联的 29.0%（P<0.05）。研究结果表明，多环芳烃暴露可能与血压升高和 ASCVD 风险增加有关。肥胖可能部分介导了多环芳烃暴露与血压升高或 ASCVD 风险增加之间的关联。
